Ghanim et al. (17) reported an improvement in iron utilization, such as decreased hepcidin and ferritin levels and increased transferrin levels, in 52 patients with type 2 diabetes treated with dapagliflozin for 12 weeks. This evidence concerns the gene HAMP and type 2 diabetes mellitus.